harvard medical school: "cgrp: a new era for migraine treatment."
.
.
advertisement
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
.
"their serious adverse incident process has been wholly inadequate and what we have heard this week is a damning indictment of the western trust.
.
.